Jefferies’ Bullish Price Target Boosts Rezolute Amid Congenital Hyperinsulinism Data Anticipation

Rezolute reported early results from its rare hypoglycemia (tumor hyperinsulinism) study of ersodetug. The company said 6 of 8 enrolled participants met the primary endpoint, achieving ≥50% reduction in intravenous glucose needs (GIR) during the 8-week pivotal phase and fully stopping IV glucose. One participant withdrew and died after hospice transition and was deemed a non-responder. Rezolute said safety remains favorable and no drug-related adverse events have been reported.

Rezolute Inc. reported positive interim Phase 3 upLIFT results for ersodetug in tumor-related hyperinsulinism. The trial enrolled 8 of 16 planned patients; 6 of the first 8 met the primary endpoint, with ≥50% reductions in IV glucose needs during the 8-week pivotal phase, and all six stopped IV glucose while on treatment. No drug-related adverse events were reported. Rezolute expects topline results in H2 2026.

GM Defense delivered missile components to Lockheed Martin in 22 days, per the companies. The deal's value and details are confidential. Both firms highlight the speed and potential for future defense collaborations.

RTX secured a multi-year contract to supply Tomahawk missiles to the U.S. Navy and allies, aiming to boost production capacity. The company delivered three times more Tomahawks in H1 2026 than H1 2025, investing in workforce and supply chain to meet demand. Tomahawk is a key long-range strike weapon for military operations.

SpaceTech Weekly Recap highlights key developments: Space42 and Viasat co-founded Equatys; Open Cosmos raised €300M; EnduroSat secured $205M; Isar Aerospace to start commercial launches; NASA awarded SpaceX three crew flights. Investors focus on scalable space infrastructure.

Adobe (ADBE) shares fell post-Q3 earnings despite beating estimates, citing forex headwinds. RPOs grew 8% YoY, the slowest since 2023. AI business ARR rose 150% but remains a small fraction of total ARR. New CEO Anil Chakravarthy will replace Shantanu Narayen. Analysts are mixed, with a mean target price of $269.70. The stock trades at 11x next fiscal year's EPS.